Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma

被引：0

作者：

Mateos, Maria-Victoria ^{[1
]}

van de Donk, Niels ^{[2
,3
]}

Delforge, Michel ^{[4
]}

Einsele, Hermann ^{[5
]}

De Stefano, Valerio ^{[6
]}

Lindsey-Hill, Joanne ^{[7
]}

Vincent, Laure ^{[8
]}

Kirkpatrick, Suriya ^{[9
]}

Besemer, Britta ^{[10
]}

Gonzalez Garcia, Maria Esther ^{[11
]}

Karlin, Lionel ^{[12
]}

Ghilotti, Francesca ^{[13
]}

Diels, Joris ^{[14
]}

Morano, Raul ^{[15
]}

Albrecht, Claire ^{[16
]}

Strulev, Vadim ^{[14
]}

Haddad, Imene ^{[16
]}

Pei, Lixia ^{[17
]}

Kobos, Rachel ^{[17
]}

Smit, Jennifer ^{[18
]}

Slavcev, Mary ^{[19
]}

Marshall, Alexander ^{[17
]}

Weisel, Katja ^{[20
]}

Moreau, Philippe ^{[21
]}

机构：

[1] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[2] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[3] Canc Ctr Amsterdam, Amsterdam, Netherlands

[4] Univ Leuven, Leuven, Belgium

[5] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[6] Catholic Univ, Fdn Policlin A Gemelli, IRCCS, Rome, Italy

[7] Nottinghamshire Univ Hosp NHS Trust, Nottingham, England

[8] CHU Montpellier, Montpellier, France

[9] Univ West England, Bristol, Avon, England

[10] Univ Hosp Tubingen, Tubingen, Germany

[11] Univ Hosp Cabuenes, Gijon, Spain

[12] Ctr Hosp Lyon Sud, Pierre Benite, France

[13] Janssen Cilag SpA, Cologno Monzese, Italy

[14] Janssen Pharmaceut NV, Beerse, Belgium

[15] Janssen Cilag, Madrid, Spain

[16] Janssen Cilag, Issy Les Moulineaux, France

[17] Janssen Res & Dev, Raritan, NJ USA

[18] Janssen Res & Dev, Spring House, PA USA

[19] Janssen Global Serv, Raritan, NJ USA

[20] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[21] Univ Hosp Hotel Dieu, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-294

引用

页码：S199 / S199

页数：1

共 50 条

[41] Real-World Study of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Medicare Patients in the United States
Delea, Thomas
Moynahan, Aaron
Ge, Wenzhen
Song, Xue
Kroog, Glenn S.
Noguera-Troise, Irene
Lorenc, Karen Rodriguez
Ma, Qiufei
BLOOD, 2023, 142
[42] Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
Tan, Carlyn Rose Co
Derkach, Andriy
Maclachlan, Kylee
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Shah, Gunjan L.
Scordo, Michael
Chung, David J.
Landau, Heather Jolie
Giralt, Sergio
Lesokhin, Alexander M.
Korde, Neha
Lin, Dee
Wu, Bingcao
Fowler, Jessica
Fernandez, Mariana
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
Kumar, Shaji
Jagannath, Sundar
Weisel, Katja C.
Dachs, Laura Rosinol
Dimopoulos, Meletios-Athanasios
Siegel, David S.
Monge, Jorge
Leleu, Xavier
Du, Juan
de la Rubia, Javier
Lee, Jae Hoon
Mateos, Maria-Victoria
Martinez, Borja Puertas
Gozzetti, Alessandro
Dytfeld, Dominik
Ocio, Enrique M.
Blade, Joan
Ozaki, Shuji
Beksac, Meral
Escalante, Fernando
Nagaraj, Madhu
Hassan, Rafla
Spin, Paul
Bonar, Nicolle
Shokoohi, Mostafa
Siddiqui, Muhaimen
Wang, Di
Hou, Kevin
Green, Jeannette
Humblet, Olivier
Breskin, Alexander
Harnett, James
Ge, Wenzhen
Sobel, Rachel E.
Jalbert, Jessica J.
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Ma, Qiufei
Hampp, Christian
Durie, Brian G. M.
BLOOD, 2024, 144 : 7012 - 7014
[44] A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
Mol, Isha
Hu, Yannan
LeBlanc, Thomas W.
Cappelleri, Joseph C.
Chu, Haitao
Nador, Guido
Aydin, Didem
Schepart, Alex
Hlavacek, Patrick
BLOOD, 2023, 142
[45] Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Kumar, Shaji
Weisel, Katja C.
Ma, Qiufei
Hampp, Christian
Humblet, Olivier
Shokoohi, Mostafa
Bonar, Nicolle
Spin, Paul
Harnett, James
Ge, Wenzhen
Jalbert, Jessica J.
Sobel, Rachel E.
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Moreau, Philippe
Usmani, Saad
van de Donk, Niels W. C. J.
Garfall, Alfred
Delforge, Michel
Oriol, Albert
Nooka, Ajay
Rosinol, Laura
Bahlis, Nizar
Rodriguez-Otero, Paula
Martin, Thomas
Diels, Joris
Van Sanden, Suzy
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Marshall, Alexander
Slavcev, Mary
Smit, Jennifer
Londhe, Anil
Krishnan, Amrita
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S182
[47] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VS BELANTAMAB MAFODOTIN FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Moreau, P.
Usmani, S. Z.
van de Donk, N. W. C. J.
Garfall, A. L.
Delforge, M.
Oriol, A.
Nooka, A.
Rosinol, L.
Bahlis, N.
Rodriguez Otero, P.
Martin, T. G.
Diels, J.
Van Sanden, S.
Pei, L.
Ammann, E.
Chastain, K.
Marshall, A.
Slavcev, M.
Londhe, A.
Krishnan, A.
VALUE IN HEALTH, 2023, 26 (12) : S5 - S6
[48] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
Dima, Danai
Davis, James A.
Ahmed, Nausheen
Sannareddy, Aishwarya
Shaikh, Hira
Mahmoudjafari, Zahra
Khouri, Jack
Kaur, Gurbakhash
Strouse, Christopher
Valent, Jason
Larry, Anderson D., Jr.
Anwer, Faiz
Abdallah, Al-Ola
Hashmi, Hamza
BLOOD, 2023, 142
[49] A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
Mol, Isha
Hu, Yannan
Leblanc, Thomas W.
Cappelleri, Joseph C.
Chu, Haitao
Nador, Guido
Aydin, Didem
Schepart, Alex
Hlavacek, Patrick
LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 660 - 668
[50] A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma
Mol, Isha
Hu, Yannan
Leblanc, Thomas W.
Cappelleri, Joseph C.
Chu, Haitao
Nador, Guido
Aydin, Didem
Schepart, Alex
Hlavacek, Patrick
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (02) : 199 - 207

← 1 2 3 4 5 →